Cadila Healthcare group has received approvals from the United States Food and Drug Association (USFDA) to market three products in quick succession namely, Lamotrigine Chewable Tablets of 2 mg, 5 mg and 25 mg, Lamotrigine Tablets of 25 mg, 50 mg and 150 mg and Divalproex Sprinkle Capsules 125 mg.
The Company will market all the three drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group now has 44 approvals since the commencement of fling process in FY 2003-04. So far, the group has tiled 80 ANDAs and 71 DMFs.